Sparks - Oryzon Genomics

Oryzon Genomics has received a ‘decision to grant’ communication from the European Patent Office for its patent application: Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat. This covers the company’s lead central nervous system candidate which, while not currently being evaluated in an active programme for attention deficit hyperactivity disorder, is involved in ongoing programmes for schizophrenia (Phase IIb trial) and borderline personality disorder (Phase III preparation underway). Once granted, this patent will remain in place until at least 2040, excluding any other potential patent term extensions. Management noted that a counterpart patent has already been granted in Japan, with further applications pending in other key regions.

In addition, Oryzon reported it has received a ‘decision to grant’ communication from the Japanese Patent Office for its patent application titled: Methods of treating autism spectrum disorder. This will be the first granted patent in this patent family, with applications pending in other countries. Once issued, this patent will also remain in place until at least 2040, excluding potential additional term extensions.